PExA

PExA is a Swedish life science and medtech company developing and commercializing a patented, non-invasive platform for collecting biological material from the small distal airways through particles in exhaled air. Its flagship instrument, PExA 2.1, is used by academic, clinical, and pharmaceutical researchers to sample respiratory tract lining fluid for biomarker discovery, disease monitoring, and translational research. The company is positioning the technology as a "liquid biopsy" for the lung and is expanding its analytical capabilities with technologies such as sPOT and RNA fragmentomics. PExA’s longer-term strategy is to translate its research-use platform into clinically deployable diagnostic products, particularly for major respiratory diseases such as lung cancer and COPD.